EASL

Human Genome Sciences Announces Second-Quarter 2009 Financial Results and Key Developments

...ry Authorities Completed - on Track for Fall Submission of Global Marketing Applications; Positive Phase 3 Results in Chronic Hepatitis C Presented at easl HGS and Novartis have selected ZALBIN as the brand name for albinterferon-alfa 2b (formerly Albuferon) in the United States. Joulferon(R) h...

The European Association for the Study of the Liver renews publishing partnership with Elsevier

...lls for Elsevier to publish the society's flagship journal, the Journal of Hepatology ( http://www.jhep-elsevier.com/ ), for the next five years. easl is a society with over 1500 members. The society has given rise to a significant number of international clinical trials and research collaborations i...

GlaxoSmithKline Travel Health: 55 percent of travellers needlessly put themselves at risk from a potentially fatal virus

... blood borne pathogens during sports: risk and prevention. Ann Int Med 1995; 122 (4): 283 8.   De Franchis et al Consensus statement, easl International Consensus Conference on Hepatitis B J Hepatol 2003; 39: S3-S25 9.   Zuckerman JN., Steffen R. J Travel Med (2000): 7;...

Future for radioembolisation in patients with advanced hepatocellular carcinoma

...ss microspheres is a safe and effective treatment for patients with advanced HCC portal vein thrombosis, according to new research presented today at easl 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark. According to the researchers, these finding...

HIV positive and HIV negative patients have similar survival rates following liver transplant

...April: HIV positive and HIV negative patients have comparable survival rates following liver transplant, according to new research presented today at easl 2009, the Annual Meeting of the European Association for the Study of Liver in Copenhagen, Denmark. The study results showed no difference in survi...

New oncogene gives valuable insight into hepatocellular tumors in humans

... Copenhagen, Denmark, Thursday 23 April: The first identification of GP130 somatic activating mutations* in human tumours was announced today at easl 2009, the Annual Meeting of the European Association for the Study of Liver Disease in Copenhagen, Denmark. Identification of recurrent somatic mut...

Liver disease responsible for most alcohol-related illness and deaths

...revalent cause of alcohol-related deaths, followed by car accidents and cancer, according to new research conducted in Portugal and presented today at easl 2009, the Annual Meeting of the European Association for the Study of Liver in Copenhagen, Denmark. The study also showed that alcohol-related disease...

First evidence for DNA-based vaccination against chronic hepatitis C

...gen, Denmark, Thursday 23 April: The first-proof-of-concept for a DNA-based therapeutic vaccination against chronic hepatitis C was announced today at easl 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark. In the first clinical trial of a therapeuti...

Diabetes, obesity and hypertension increase mortality in hepatitis C patients

...The specific impact of metabolic syndrome on mortality in hepatitis C patients has been revealed by new research to be presented on Sunday April 26 at easl 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark. According to the results of the research, t...

International Liver Congress 2009

...in Copenhagen, Denmark. Press registration is free of charge for all holders of a valid press card / formal journalist credentials. The official easl press conference will be held from 13.15 to 14.15 CET on Wednesday 22nd April. This will be preceded by a finger buffet for press and speakers from 1...

More>>

EASL in Medical Technology

Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C

- With half as many injections, in two pivotal Phase 3 trials, Albuferon (albinterferon alfa-2b) met the primary efficacy endpoint of sustained virologic response comparable to Pegasys (peginterferon alfa-2a) - - Patients receiving 900-mcg Albuferon had comparable rates of serious and...

Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008

Findings Include 80% SVR12 Rate with Nitazoxanide-Based Combination Therapy and New Insights into Mechanism of Action of Nitazoxanide MILAN, Italy, April 23 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced that data from studies of nitazoxani...

Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL

MILAN, Italy, April 26 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP ) today reported that results from a planned interim analysis of an ongoing Phase II study of boceprevir, its investigational oral hepatitis C protease inhibitor, in 595 treatment-naive patients with chronic hepatit...

Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C

BARCELONA, Spain--(BUSINESS WIRE)--Apr 14, 2007 - In a late-breaker presentation at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL), researchers today presented data from a planned interim analysis of the PROVE 1 clinical trial, which is the first trial to eval...

Achillion Presents Positive Data on Novel Mechanism for Treating HCV at EASL Annual Meeting

-NS4A Antagonist Demonstrates Clinical Activity, a Novel Mechanism of Action and In Vitro Compatibility with other HCV Inhibitors- NEW HAVEN, Conn., April 16, 2007 /PRNewswire-FirstCall/ -- Achillion Pharmaceuticals, Inc. today announced the presentation of data validating the clinical antiviral a...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

...s for HCV. Dial-In and Webcast Details InterMune and Pharmasset will host a live webcast of a discussion of the INFORM-1 results from the easl conference today, Saturday, April 25, 2009, at 7:00 p.m. CEST (1:00 p.m. EDT). Participating in the discussion will be Dr. Ed Gane, principal investi...

InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)

...nterferon or ribavirin, known as the INFORM-1 study. Interim results from the INFORM-1 study will be presented in an oral late-breaker session of the easl meeting on Saturday, April 25, 2009. About InterMune InterMune is a biotechnology company focused on the research, development and commerc...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

...ta Being Presented Today at 44th Annual Meeting of easl Management to Discuss Study Results and Progr...on and ribavirin. ANA598 Preclinical Data at easl Meeting In addition to the results of the Phase...l data on the preclinical profile of ANA598 at the easl Meeting at 4 p.m. CEST (7 a.m. PDT) on Friday, Apr...

Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

...ion HCV protease inhibitor SCH 900518 presented at easl annual meeting COPENHAGEN, Denmark, April 23 ...8 (Next-Generation HCV Protease Inhibitor) Data at easl Researchers at easl also presented early phase clinical data for SCH 9...

Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients

...e. Our partner Roche will shortly initiate dosing in a phase 2b trial with R7128, and will report interim data from the INFORM-1 trial at the upcoming easl meeting. Pharmasset's unpartnered second generation HCV nucleoside, PSI-7851, is progressing well in a phase I trial and we expect to report the first...

More>>

EASL in Biological News

Biolex presents Locteron US Phase 2a hepatitis C data at EASL

Biolex Therapeutics, Inc. announced that the results from its United States Phase 2a clinical trial (the "PLUS" trial) of Locteron will be presented today at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark. Locteron, controlled-release i...

EASL in Biological Technology

InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25

-- Conference Call and Webcast Scheduled -- BRISBANE, Calif., April 20 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that InterMune and Pharmasset, Inc. will host a live webcast of a discussion of the INFORM-1 results from the EASL conference on Saturday, April 2...

InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting

BRISBANE, Calif., March 18 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that five abstracts from clinical and in-vitro studies of ITMN-191 (R7227) and the company's research programs related to the hepatitis C virus (HCV) have been accepted for presentation at the 44...

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

...N-191 treatment in any cohort. ITMN-191 plus standard-of-care therapy was safe and generally well tolerated. Also at the easl meeting in late April, InterMune, Roche and Pharmasset, Inc. reported initial results from the novel Phase 1 INFORM-1 clinical trial evaluating ITMN-1...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

...at all dose levels in a Phase Ib study in HCV patients were reported at the easl conference. The median viral load reduction over three days ranged from 2....portion of the Phase I clinical trial of ANA773 in HCV were reported at the easl conference. ANA773 was generally well tolerated with no serious adverse ev...

Pharmasset Reports Fiscal Second Quarter 2009 Financial Results

...o make solid progress," stated Schaefer Price, President and Chief Executive Officer. "In April, we announced exciting data from the INFORM-1 trial at easl and the initiation of the phase 2b trial with R7128. We are now able to increase our focus on further strengthening our portfolio of HCV nucleos(t)ide...

Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments

...esults Announced for Second of Two Phase 3 Trials of Albuferon (R) in Chronic Hepatitis C; Late-Breaker Results of Both Phase 3 Trials Presented at easl In March 2009, HGS reported that Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority to Pegasys (peginterferon alfa-2a...

Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights

... Preclinical Data at easl . On April 24, Anadys will present additional data on the preclinical profile of ANA598 at the easl meeting in an oral presentation titled, "Preclinic...f ANA773 in HCV are being presented in a poster at easl titled, "PK/PD Assessment of a Phase I Healthy Vol...

Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver

...day study in HCV-infected chimpanzees, in which six genotype-1 infected chimpanzees received 10 mg/kg of IDX184 daily for four days. Data presented at easl confirm a pharmacokinetic/pharmacodynamic (PK/PD) relationship between nucleoside metabolite concentrations in serum and viral load reductions in this...

INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients

...er presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL), to be presented on Saturday, April 25 at the easl meeting in Copenhagen, Denmark. The abstract can be viewed at www.easl.ch About InterMune InterMune is a biotechnology company focused ...

Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)

...ting of the European Association for the Study of the Liver (EASL, April 22-26, 2009 in Copenhagen, Denmark). Full abstracts can now be viewed at the easl website at www.easl.ch . The four accepted abstracts are as follows: ANTIVIRAL ACTIVITY OF THE LIVER-TARGETED NUCLEOTIDE HC...